India Markets closed

Cadila Healthcare gets final approval for multiple cadicsclerosis drug

·1-min read

Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS). Cadila said the drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

Furthermore, the company added as also received a final approval from the USFDA to market Verapamil Hydrochloride Injection. Verapamil injection is used to rapidly or temporarily restore normal heartbeats in people with certain heart rhythm disorders. Cadila said the injections will be manufactured at the company's manufacturing facility at Jarod, near Vadodara.

The group now has 305 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

On a consolidated basis, the company's net profit surged 49.53% to Rs 454 crore on 4.20% rise in revenue from operations to Rs 3,549.30 crore in Q1 June 2020 over Q1 June 2019.